G Senti

Summary

Affiliation: University Hospital
Country: Switzerland

Publications

  1. ncbi request reprint A cutaneous allergen neutralisation test that correlates with the duration of venom immunotherapy
    Gabriela Senti
    Unit for Experimental Immunotherapy, Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Int Arch Allergy Immunol 141:377-83. 2006
  2. ncbi request reprint Evaluation of visual analog scales for the assessment of symptom severity in allergic rhinoconjunctivitis
    Gabriela Senti
    Unit for Experimental Immunotherapy, Department of Dermatology, University of Zurich, Zurich, Switzerland
    Ann Allergy Asthma Immunol 98:134-8. 2007
  3. doi request reprint Intralymphatic immunotherapy
    Gabriela Senti
    Clinical Trials Center, Center for Clinical Research, University and University Hospital of Zurich, Switzerland
    Curr Opin Allergy Clin Immunol 9:537-43. 2009
  4. doi request reprint Intralymphatic immunotherapy: from the rationale to human applications
    Gabriela Senti
    Clinical Trials Center, Center for Clinical Research, University and University Hospital of Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    Curr Top Microbiol Immunol 352:71-84. 2011
  5. pmc EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy
    Moises A Calderon
    Section of Allergy and Clinical Immunology, Imperial College, National Heart and Lung Institute, Dovehouse Street, London, SW3 6LY, UK
    Clin Transl Allergy 2:20. 2012
  6. doi request reprint Epicutaneous/transcutaneous allergen-specific immunotherapy: rationale and clinical trials
    Gabriela Senti
    Clinical Trials Center, Center for Clinical Research, University Hospital Zurich, Zurich, Switzerland
    Curr Opin Allergy Clin Immunol 10:582-6. 2010
  7. ncbi request reprint Antimicrobial silk clothing in the treatment of atopic dermatitis proves comparable to topical corticosteroid treatment
    G Senti
    Unit for Experimental Immunotherapy, Department of Dermatology, University of Zurich, Zurich, Switzerland
    Dermatology 213:228-33. 2006
  8. doi request reprint Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial
    G Senti
    Unit for Experimental Immunotherapy, Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Clin Exp Allergy 39:562-70. 2009
  9. ncbi request reprint Toll-like receptor ligands as adjuvants in allergen-specific immunotherapy
    P Johansen
    Unit for Experimental Immunotherapy, University Hospital of Zurich, Zurich, Switzerland
    Clin Exp Allergy 35:1591-8. 2005
  10. ncbi request reprint Medication with antihistamines impairs allergen-specific immunotherapy in mice
    P Johansen
    Unit for Experimental Immunotherapy, Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    Clin Exp Allergy 38:512-9. 2008

Collaborators

  • T M Kundig
  • P Johansen
  • B Wuthrich
  • P Schmid-Grendelmeier
  • Reto Crameri
  • Adrian Bot
  • M F Bachmann
  • B Fischer
  • M Steiner
  • U Ackermann-Liebrich
  • F Tay
  • Karl S Lang
  • S von Moos
  • Moises A Calderon
  • Julia M Martínez-Gómez
  • J M Martínez-Gómez
  • N Graf
  • S Haug
  • Carmen Moreno
  • Giovanni Pajno
  • Peter Eng
  • Antonio Nieto
  • Ludger Klimek
  • Beatrice Bilo
  • Y Waeckerle-Men
  • Aziz Sheikh
  • Emilio Alvarez-Cuesta
  • Jörg Kleine-Tebbe
  • Alain Didier
  • Bodo Niggemann
  • Johannes C Virchow
  • Ronald Dahl
  • Nikolaos Papadopoulos
  • Jocelyne Just
  • Albrecht Bufe
  • Lars Jacobsen
  • Jean Bousquet
  • Walter G Canonica
  • Oliver Pfaar
  • Pascal Demoly
  • Hans J Malling
  • Carmen Vidal
  • Ulrich Wahn
  • Victoria Cardona
  • Marianne van Hage
  • D Mohanan
  • Eva M Varga
  • Claus Bachert
  • Montserrat Fernandez-Rivas
  • Jan Lotvall
  • Ralph Mosges
  • Antonella Muraro
  • Rudolph Valenta
  • Roy Gerth van Wijk
  • Glenis Scadding
  • Barbara Bohle
  • Giovanni Passalacqua
  • Sabina Rak
  • Erkka Valovirta
  • Stephen R Durham
  • Cezmi Akdis
  • Marek Jutel
  • A Haffner
  • Gianenrico Senna
  • Anthony Frew
  • H Rose
  • Iris Erdmann
  • C Rhyner
  • M Gassner
  • C Schindler
  • A Roll

Detail Information

Publications28

  1. ncbi request reprint A cutaneous allergen neutralisation test that correlates with the duration of venom immunotherapy
    Gabriela Senti
    Unit for Experimental Immunotherapy, Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Int Arch Allergy Immunol 141:377-83. 2006
    ..Therefore, we aimed to develop a cutaneous test that measures in vivo neutralisation of the Hymenoptera venom...
  2. ncbi request reprint Evaluation of visual analog scales for the assessment of symptom severity in allergic rhinoconjunctivitis
    Gabriela Senti
    Unit for Experimental Immunotherapy, Department of Dermatology, University of Zurich, Zurich, Switzerland
    Ann Allergy Asthma Immunol 98:134-8. 2007
    ..However, NPTs are time-consuming and stressful for patients; therefore, recording of symptoms during natural allergen exposure on visual analog scales (VASs) is increasingly being used in clinical trials...
  3. doi request reprint Intralymphatic immunotherapy
    Gabriela Senti
    Clinical Trials Center, Center for Clinical Research, University and University Hospital of Zurich, Switzerland
    Curr Opin Allergy Clin Immunol 9:537-43. 2009
    ..Recently, immunotherapy by direct administration of the allergen into lymph nodes [intralymphatic immunotherapy (ILIT)] has proven a promising alternative and this method is the focus of the present review...
  4. doi request reprint Intralymphatic immunotherapy: from the rationale to human applications
    Gabriela Senti
    Clinical Trials Center, Center for Clinical Research, University and University Hospital of Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    Curr Top Microbiol Immunol 352:71-84. 2011
    ....
  5. pmc EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy
    Moises A Calderon
    Section of Allergy and Clinical Immunology, Imperial College, National Heart and Lung Institute, Dovehouse Street, London, SW3 6LY, UK
    Clin Transl Allergy 2:20. 2012
    ....
  6. doi request reprint Epicutaneous/transcutaneous allergen-specific immunotherapy: rationale and clinical trials
    Gabriela Senti
    Clinical Trials Center, Center for Clinical Research, University Hospital Zurich, Zurich, Switzerland
    Curr Opin Allergy Clin Immunol 10:582-6. 2010
    ..The epidermis, a nonvascularized multilayer epithelium that contains high numbers of potent antigen-presenting Langerhans cells, could therefore be an interesting administration route...
  7. ncbi request reprint Antimicrobial silk clothing in the treatment of atopic dermatitis proves comparable to topical corticosteroid treatment
    G Senti
    Unit for Experimental Immunotherapy, Department of Dermatology, University of Zurich, Zurich, Switzerland
    Dermatology 213:228-33. 2006
    ..Atopic dermatitis (AD) is aggravated by mechanical irritation and bacterial colonization...
  8. doi request reprint Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial
    G Senti
    Unit for Experimental Immunotherapy, Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Clin Exp Allergy 39:562-70. 2009
    ..Therefore, the phase I/IIa study presented represents the first test of A-type CpGs in humans...
  9. ncbi request reprint Toll-like receptor ligands as adjuvants in allergen-specific immunotherapy
    P Johansen
    Unit for Experimental Immunotherapy, University Hospital of Zurich, Zurich, Switzerland
    Clin Exp Allergy 35:1591-8. 2005
    ..The major disadvantage of SIT is its low efficiency, requiring treatment over years...
  10. ncbi request reprint Medication with antihistamines impairs allergen-specific immunotherapy in mice
    P Johansen
    Unit for Experimental Immunotherapy, Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    Clin Exp Allergy 38:512-9. 2008
    ..Histamine released from activated mast cells and basophils is an important mediator in allergy. Therefore, antihistamines are efficiently and widely used to suppress allergic symptoms...
  11. doi request reprint The contact sensitizer diphenylcyclopropenone has adjuvant properties in mice and potential application in epicutaneous immunotherapy
    S von Moos
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Allergy 67:638-46. 2012
    ..Such barrier function of the stratum corneum also hampers the use of common adjuvants used to enhance the efficacy of vaccination...
  12. doi request reprint Targeting the MHC class II pathway of antigen presentation enhances immunogenicity and safety of allergen immunotherapy
    J M Martínez-Gómez
    Unit for Experimental Immunotherapy, Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    Allergy 64:172-8. 2009
    ..The aim of this study was to test whether modified recombinant allergens can improve therapeutic efficacy in SIT while reducing allergic side-effects...
  13. ncbi request reprint Double-blind, placebo-controlled study with sublingual immunotherapy in children with seasonal allergic rhinitis to grass pollen
    B Wuthrich
    Allergy Unit, Department of Dermatology, University Hospital, Zurich, Switzerland
    J Investig Allergol Clin Immunol 13:145-8. 2003
    ..The purpose of this study was to assess the efficacy and tolerance of SLIT in children who are sensitized to grass pollen...
  14. ncbi request reprint Coated textiles in the treatment of atopic dermatitis
    S Haug
    Allergy Unit, Department of Dermatology, University Hospital of Zurich, Switzerland
    Curr Probl Dermatol 33:144-51. 2006
    ..Silk can be coated with antimicrobials (Dermasilk). The combination of the smoothness of silk with an antimicrobial finish appears to make an ideal textile for patients suffering from AD...
  15. ncbi request reprint Efficacy and safety of allergen-specific immunotherapy in rhinitis, rhinoconjunctivitis, and bee/wasp venom allergies
    G Senti
    Department of Dermatology, University Hospital of Zurich, Switzerland
    Int Rev Immunol 24:519-31. 2005
    ..This review describes and discusses these new developments in the context of the many recent advances in our understanding of the mechanisms by which immunotherapy appears to act...
  16. ncbi request reprint Direct intralymphatic injection of peptide vaccines enhances immunogenicity
    P Johansen
    Department of Dermatology, University of Zurich, Zurich, Switzerland
    Eur J Immunol 35:568-74. 2005
    ..These results should have immediate implications for clinical immunotherapy of infectious disease and cancer...
  17. ncbi request reprint Analysis of the relationship between pollinosis and date of birth in Switzerland
    N Graf
    Unit for Experimental Immunotherapy, Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    Int Arch Allergy Immunol 143:269-75. 2007
    ..The objective of this study was to examine the relationship between the month of birth and the development of birch and grass pollen allergy in the Swiss population...
  18. ncbi request reprint Heat denaturation, a simple method to improve the immunotherapeutic potential of allergens
    Pål Johansen
    Unit for Experimental Immunotherapy, University Hospital of Zurich, Zurich, Switzerland
    Eur J Immunol 35:3591-8. 2005
    ..This enables Th1 skewing of the immune response with strong production of IgG2a in mice. Therefore, heat-denaturation represents probably the simplest way to enhance the efficiency of SIT while reducing its side effects...
  19. ncbi request reprint Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults
    Thomas M Kundig
    University of Zurich, Department of Dermatology, University Hospital Zurich, Switzerland
    J Allergy Clin Immunol 117:1470-6. 2006
    ..In this study we covalently coupled a synthetic 16-amino-acid sequence of the allergen Der p 1 to a virus-like particle derived from the bacteriophage Qbeta (Qbeta-Der p 1)...
  20. doi request reprint [Allergen specific immunotherapy: new approaches]
    F Tay
    Clinical Trials Center, Zentrum für Klinische Forschung, Universitätsspital und Universität Zürich, Zurich
    Praxis (Bern 1994) 99:1279-84. 2010
    ..e. administration of allergens using a skin patch, are under investigation in clinical trials at the Zurich University Hospital...
  21. doi request reprint Epicutaneous allergen administration: is this the future of allergen-specific immunotherapy?
    G Senti
    Clinical Trials Center, University Hospital of Zurich, Zurich, Switzerland
    Allergy 66:798-809. 2011
    ..The present review will discuss the immunological rational, history and actual clinical experience with epicutaneous allergen-specific immunotherapy...
  22. doi request reprint Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy
    Gabriela Senti
    Unit for Experimental Immunotherapy, University Hospital of Zurich, Zurich, Switzerland
    J Allergy Clin Immunol 124:997-1002. 2009
    ..Transcutaneous immunotherapy may improve patient compliance and safety...
  23. doi request reprint Intralymphatic injections as a new administration route for allergen-specific immunotherapy
    Julia M Martínez-Gómez
    Unit for Experimental Immunotherapy, Department of Dermatology, University Hospital of Zurich, Zurich CH 8091, Switzerland
    Int Arch Allergy Immunol 150:59-65. 2009
    ..To improve the safety and attractiveness of SIT for patients, alternative routes of allergen administration are being explored, such as sub-lingual or oral administration...
  24. pmc Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial
    Gabriela Senti
    Unit for Experimental Immunotherapy, Department of Dermatology, University Hospital Zurich, 8091 Zurich, Switzerland
    Proc Natl Acad Sci U S A 105:17908-12. 2008
    ..001), and was less painful than venous puncture (P = 0.018). In conclusion, intralymphatic allergen administration enhanced safety and efficacy of immunotherapy and reduced treatment time from 3 years to 8 weeks...
  25. doi request reprint Nickel sensitisation in mice: a critical appraisal
    Pål Johansen
    Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, 8091 Zurich, Switzerland
    J Dermatol Sci 58:186-92. 2010
    ....
  26. ncbi request reprint Immunotherapeutic targeting of allergic disease
    Gabriela Senti
    Unit for Experimental Immunotherapy, Department of Dermatology, University Hospital of Zurich, Switzerland
    Inflamm Allergy Drug Targets 5:243-52. 2006
    ..This review describes and discusses these new developments in the context of the many recent advances in our understanding of the mechanisms by which immunotherapy appears to act...
  27. pmc Antigen kinetics determines immune reactivity
    Pål Johansen
    Unit Experimental Immunotherapy, Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, CH 8091 Zurich, Switzerland
    Proc Natl Acad Sci U S A 105:5189-94. 2008
    ..In conclusion, stimulation kinetics per se was shown to be a separate parameter of immunogenicity. These findings warrant a revision of current immunization models and have implications for vaccine development and immunotherapy...
  28. ncbi request reprint Atopic eczema: genetics or environment?
    Brunello Wuthrich
    Spital Zollikerberg, Allergologie, klinische Immunologie und Dermatologie, Trichtenhauserstrasse 20, 8125 Zollikerberg, Switzerland
    Ann Agric Environ Med 14:195-201. 2007
    ..From the therapeutic point of view, besides emollients and local corticosteroids, topic immunomodulatory drugs (tacrolimus and pimecrolimus) have substantially improved the treatment of AE...